Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SIOX buy 0.430600
nice exhaustion gap and now reversal buy
find the massive macd bullish divergence on the daily and weekly charts
it just broke above the downtrend line as a buy trigger for the setup
up we go
https://siogtx.com/
https://finance.yahoo.com/quote/SIOX/profile?p=SIOX
https://www.barchart.com/stocks/quotes/SIOX
https://finviz.com/quote.ashx?t=SIOX
https://www.stockconsultant.com/consultnow/basicplus.cgi?symbol=SIOX
https://stockcharts.com/c-sc/sc?chart=SIOX,uu[e,a]dhclyiay[uu][pb5!b10!b50!b100!b200!d20,2!h.02,.20!f][vb5!b20][iut!lv8!lk9!LE12,26,9!ll14!la6,13,5!la8,17,9!la12,26,9!uc14!ub14!ub6!lo!lp7,3!lh9,3!LI14,3!lxa!ld8!lq!lg14!lf14][j20444984,y]&r=3555b
https://www.barchart.com/etfs-funds/quotes/SIOX/technical-chart?plot=CANDLE&volume=toSIOX&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=TREND&sym=SIOX&grid=1&height=500&studyheight=100&timeframe=2%20Months
normal chart
log chart
normal chart
log chart
Another small cap bio that won't hunt. Below cash value too. Got out and the last bio I'll play. They're all dogs with zero return on investment monies.
News and PPS down again and again. Stioll watch.
SIOX
Trading at cash value. Price target 1 dollar. Operations in full buyout now IMO.
Over 30% below cash value, with a potential Parkinson's treatment. Amazing times..
Currently below tangible book value here. With the Parkinson's prom is potential promise of a viable treatment, can the market cap be any more insulting?
Within 6 months SIOX could easily be 1000% (10X) higher than its current price.
Good luck and GOD bless,
TODAY’s update from Sio Gene Therapies
https://investors.siogtx.com/news-releases/news-release-details/sio-gene-therapies-announces-corporate-updates-and-fiscal-second
Good luck and GOD bless,
Regard SIOX and AXO-lento- PD
See slides 32 thru 37 inclusive
https://www.oxb.com/system/files/corporate-presentations/OXB%20Presentation%2027%20Oct%2021%20w%20appendix.pdf
Good luck and GOD bless,
GREAT news this morning 3 batches at date I say 200 liter batch size.
That is EXCELLENT NEWS. That should be enough material to treat 10s of thousands if not hundreds of thousands of men and women with Parkinson’s’ disease.
Ready for commercialization.
“Today’s announcement is the culmination of several months of effort by the Sio and Oxford BioMedica teams focused on the development of a reliable, suspension-based manufacturing process to enable scale-up of production and advancement of the AXO-Lenti-PD program,” said Pavan Cheruvu, M.D., Chief Executive Officer of Sio Gene Therapies. “With the successful manufacture of three batches, all of which achieved the target titer and have completed fill and finish, we now have a process that has generated sufficient clinical trial material for future clinical development. We believe these data, coupled with scientific advice from the MHRA, help clarify the path forward and collectively represent an inflection point for the AXO-Lenti-PD program.”
https://finance.yahoo.com/news/sio-gene-therapies-announces-successful-120000897.html
Good luck and GOD bless,
I think the CEO is hoping the WSB’s picks up on this ‘break through’ PR, lmao:
Sio Gene Therapies Announces Successful Manufacture of ‘Three GMP Batches’ of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease
Please, pray for all the participants in the SIO Gene Therapy trials.
Pray that the gene therapies are successful.
Good luck and GOD bless,
The Future
• SIGMAR1 to open up new opportunities Beyond the Horizon
- Expanded CNS indications - Regenerative medicine1
- Disease prevention2
https://e1cd7807-443e-425e-9433-41548681800c.filesusr.com/ugd/73f698_021c7a1cb7a24d78b02dac05e7262ef7.pdf
Good luck and GOD bless,
Why haven't we seen the presentation and poster regarding the following:
Presentation Title: Bicistronic AAV Gene Therapy for Tay-Sachs and Sandhoff Diseases in a Sheep Model
Presentation Number: OR30
Session: Session 4a: CNS & Sensory II
Presenting Author: Toloo Taghian, Ph.D., University of Massachusetts
Presentation Date and Time: Thursday, October 21, 2021; 9:00-11:00 AM CEST
Poster Presentation Details:
Presentation Title: Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease: Efficacy, Safety, and Tolerability Data up to 24 Months
Poster Number: P254
Presenting Author: Gavin Corcoran, MD, Chief R&D Officer of Sio Gene Therapies
Good luck and GOD bless,
Sio Gene Therapies Announces Reorganization of R&D Group
https://www.globenewswire.com/news-release/2021/10/21/2318825/0/en/Sio-Gene-Therapies-Announces-Reorganization-of-R-D-Group.html
Should we expect heavy buying as the stock price goes up and up and up into the close of trading at 4:00 PM EDT today?
Good luck and GOD bless,
Over 20 million shares of SIOX were purchased so far TODAY!!!
Good luck and GOD bless,
SIOX key quotes
https://pulse2.com/sio-gene-therapies-nasdaq-siox-stock-why-it-increased-today/
KEY QUOTES:
“Our team continues to lead the industry in the development of a new, potentially disease-modifying therapeutic option for GM1 gangliosidosis. We are extremely proud of these data, representing our broadest dataset generated thus far, which support a dose response and a favorable safety and tolerability profile at both low and high doses. We observed dose-dependent responses in two key biomarkers, serum ß-galactosidase and cerebrospinal fluid (CSF) GM1 ganglioside, including normalization of both biomarkers in the high-dose cohort. Taken together, six out of seven patients show no evidence of overt disease progression at the latest timepoint assessed, and we now have a better understanding of the clinical measures that may serve as important indicators of efficacy. Based on the results of this ongoing study, we are working on the continued development of AXO-AAV-GM1 and plan to engage the FDA to discuss further development, recognizing that there is currently no approved therapy available for GM1 patients.”
— Gavin Corcoran, M.D., Chief R&D Officer of Sio Gene Therapies
“I have dedicated my career to the care of patients with GM1 gangliosidosis and to research efforts in the search for a functional cure. The biomarker dose response and favorable safety profile is a remarkable finding for the gene therapy field. I am excited about the potential impact that AXO-AAV-GM1 may have on the lives of these children and their families. I look forward to seeing the longer-term data, where we may have a chance to see not only durable disease stabilization, but possibly even improvement.”
I couldn't agree with you more, georgejjl!
Look at slides 19 through 31 inclusive
https://investors.siogtx.com/static-files/c1199765-b3af-45d8-a8b8-d78ec3c106fa
Good luck and GOD bless,
Over 7 million shares traded in the first 30 minutes of trading!!!
Good luck and GOD bless,
The ABSOLUTE BEST NEWS is that children are being treated and responding well for a condition that up to now has been fatal.
FDA FAST TRACK FAST!!!
Good luck and GOD bless,
SIOX: Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene Therapy in Patients with GM1 Gangliosidosis
https://finance.yahoo.com/news/sio-gene-therapies-announces-granting-120000153.html
Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis
https://investors.siogtx.com/news-releases/news-release-details/sio-gene-therapies-announces-positive-interim-safety-and
Good luck and GOD bless,
Chitotriosidase as a biomarker for gangliosidoses
Sarah Kim 1 2, Chester B Whitley 1 2 3, Jeanine R Jarnes 1 2
Affiliations collapse
Affiliations
1Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, 7-115 Weaver-Densford Hall, 308 Harvard St. S.E., Minneapolis, MN 55455, USA.
2Gene Therapy and Diagnostics Laboratory, Department of Pediatrics, University of Minnesota, 420 Delaware St SE, MMC 391, Minneapolis, MN 55455, USA.
3Advanced Therapies Program, University of Minnesota-Fairview, 420 Delaware St SE, MMC 391, Minneapolis, MN 55455, USA.
PMID: 34646735 PMCID: PMC8498089 DOI: 10.1016/j.ymgmr.2021.100803
Free PMC article
Abstract
Elevated serum chitotriosidase (CHITO) is an indication of macrophage activation, and its capacity have been explored as a marker of inflammation in a number of disease states. For over a decade, CHITO plasma levels have been used by clinicians as a biomarker of inflammation in the lysosomal disease, Gaucher disease, including monitoring response to therapies in patients with Gaucher disease type I. Although it is becoming increasingly recognized that inflammation is a prominent component of many lysosomal diseases, the relation of CHITO levels to disease burden has not been well-characterized in the large majority of lysosomal diseases. Moreover, the role of CHITO in lysosomal diseases that affect the central nervous system (CNS) has not been systematically studied. In this study, one hundred and thirty-four specimens of CSF and serum were collected from 34 patients with lysosomal diseases affecting the CNS. This study included patients with GM1-gangliosidosis, GM2-gangliosidosis, mucopolysaccharidoses (MPS), multiple sulfatase deficiency and Gaucher disease. CHITO levels in the CSF were significantly higher in patients with more rapidly progressing severe neurological impairment: GM1-gangliosidosis vs MPS (p < 0.0001); GM2-gangliosidosis vs MPS (p < 0.0001). CHITO levels were higher in patients with the more severe phenotypes compared to milder phenotypes in GM1-gangliosidosis and GM2-gangliosidosis (serum CHITO in GM1-gangliosidosis infantile vs juvenile p = 0.025; CSF CHITO in Tay-Sachs infantile vs Tay-Sachs late-onset p < 0.0001). Moreover, higher CHITO levels in the CSF were significantly associated with lower cognitive test scores in patients with GM1-gangliosidosis, GM2-gangliosidosis, and MPS (p = 1.12*10-5, R2 = 0.72). Patients with infantile GM1-gangliosidosis showed increasing CSF CHITO over time, suggesting that CSF CHITO reflects disease progression and a possible surrogate endpoint for future clinical trials with infantile GM1-gangliosidosis. In summary, these results support the use of CSF CHITO to diagnose between different disease phenotypes and as a valuable tool for monitoring disease progression in patients. These results necessitate the inclusion of CHITO as an exploratory biomarker for clinical trials.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498089/
Good luck and GOD bless,
Corporate Presentations
More information is coming soon.
https://investors.siogtx.com/
Good luck and GOD bless,
It appears that the pre-clinical results are very very good for the Bicistronic AAV gene therapy for Tay-Sachs and Sandhoff diseases in a sheep model especially when injected via cerebrospinal fluid (CSF)
"...CSF treated sheep are ongoing with the oldest now more than 3 years old. Untreated TSD sheep reach humane endpoint at ~9 months...."
"...GM2 levels in CSF of sheep treated by CSF administration were normalized starting at 1 month after treatment and remained in normal range up to 2 years...."
"...CSF treatment resulted in HexA activity at above normal levels in central nervous system (CNS)...."
"...Magnetic resonance spectroscopy of treated sheep thalamus showed normalization of neuronal health markers, myelination and metabolism in CSF cohort...."
"...Both cohorts exhibited marked attenuation of neurologic disease and normal cognition in neurological examination...."
Bicistronic AAV gene therapy for Tay-Sachs and Sandhoff diseases in a sheep model
T Taghian D Fernau K Mercado L Ellis E Diffie A Gross A Maguire A Batista S Bertrand M Otero R Prestigiacomo R Gately J Gallagher H Lahey A Taylor J Koehler D Martin M Sena-Esteves1 H Gray-Edwards
1: University of Massachusetts Medical School 2: Auburn University 3: Tufts Cummings School of Veterinary Medicine
Tay-Sachs and Sandhoff diseases (TSD, SD) are fatal neurodegenerative disorders, caused by mutations in alpha or beta subunit of enzyme Hexosaminidase (Hex), respectively, and result in GM2 ganglioside storage and neuronal death. Here we describe therapeutic efficacy of a bicistronic AAV9 vector construct in naturally occurring sheep model of TSD. TSD sheep were injected with 1E14 vg total intravenously (IV, n=5) or via cerebrospinal fluid (CSF, n=9). Sheep treated IV survived to 18?±?5 months and CSF treated sheep are ongoing with the oldest now more than 3 years old. Untreated TSD sheep reach humane endpoint at ~9 months. GM2 levels in CSF of sheep treated by CSF administration were normalized starting at 1 month after treatment and remained in normal range up to 2 years, however, GM2 levels in IV cohort remained above normal. CSF treatment resulted in HexA activity at above normal levels in central nervous system (CNS), however, for IV cohort only lumbar spinal cord reached normal level. HexA expression in peripheral nervous system (PNS) was similar for both cohorts. GM2 levels in CNS and PNS were in line with HexA levels. Vector genome content in CNS was consistent with HexA levels, however, IV treatment except for optic nerve resulted in higher number of virus particles in PNS. Magnetic resonance spectroscopy of treated sheep thalamus showed normalization of neuronal health markers, myelination and metabolism in CSF cohort and slight improvements in IV cohort. Both cohorts exhibited marked attenuation of neurologic disease and normal cognition in neurological examination.
Good luck and GOD bless,
It appears there are very very good results for the Phase 1/2 Trial of AXO-AAV-GM1 Gene Therapy for the Treatment of Infantile- and Juvenile-onset GM1 Gangliosidosis:
Phase 1/2 Trial of AXO-AAV-GM1 Gene Therapy for the Treatment of Infantile- and Juvenile-onset GM1 Gangliosidosis
C Tifft12 P D'Souza12 J M Johnston12 M T Acosta12 E R Nicoli12 C Rothermel12 A Thurm13 A Karunakara4 B Thorp4 P Ross4 J Jameson4 M Sheehan4 T Vaughn4 D Valencia4 E De Boever4 G Corcoran4
1: National Institutes of Health 2: National Human Genome Research Institute 3: National Institute of Mental Health 4: Sio Gene Therapies Inc.
Data is presented from an ongoing open-label, single-arm, dose-ranging Phase 1/2 trial (NCT03952637) of an investigational gene therapy AXO-AAV-GM1 (AAV9-GLB1) for treatment of GM1 gangliosidosis which is a rare, fatal, neurodegenerative lysosomal storage disorder. Subjects are administered AXO-AAV-GM1 intravenously following immune modulation with rituximab, sirolimus and glucocorticoids. Seven subjects have been enrolled in 2 cohorts: low-dose (1.5x1013 vg/kg), n?=?4 late-infantile-onset and n?=?1 juvenile-onset, follow-up 12-months; high-dose (4.5x1013 vg/kg), n?=?2 juvenile-onset, follow-up 6-months. AXO-AAV-GM1 was generally safe and well-tolerated. There were two serious adverse events unrelated to AXO-AAV-GM1. Six subjects had adverse events of AST or ALT elevations (≤5X above baseline) that did not require clinical intervention or have associated clinical sequelae and no adverse events of elevations in GGT or bilirubin were reported. At 6-months, CSF GM1 ganglioside was reduced to published normal levels and serum ß-gal enzyme activity increased above the lower limit of normal reference levels in the high-dose subjects. At 12-months, the CSF GM1 ganglioside remained below baseline levels in all low-dose subjects and serum ß-gal activity remained above baseline levels in two of five subjects. Volumetric MRI data in low-dose subjects showed maintenance of brain volume in four of five subjects at 12-months. There was no clinical evidence of disease progression in four of five low-dose subjects at 12-months or in the high-dose cohort at 6-months post-treatment as assessed by Vineland-3, Upright/Floor Mobility Score, Clinical Global Impression, and neurological examination. Further evaluation of these subjects is ongoing
Good luck and GOD bless,
Great volume going into Thursday's presentations.
Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson's Disease: Efficacy, Safety, and Tolerability Data up to 24 Months
G Corcoran1 A Karunakara1 E Dumayas1 D Valencia1 E De Boever1 T Foltynie2 R A Barker3 S Palfi4
1: Sio Gene Therapies 2: UCL Institute of Neurology 3: Addenbrooke's Hospital 4: Groupe Hospitalier Henri-Mondor
AXO-Lenti-PD uses a lentiviral vector that includes the three genes required for endogenous dopamine synthesis (TH, CH1 and AADC) and is delivered via one-time direct bilateral infusions into each putamen. Six subjects have been enrolled in 2 cohorts in the Phase 1/2 SUNRISE-PD study (NCT03720418): low-dose (4.2E+6 TU), n?=?2, follow-up 24-months; mid-dose (1.4E+7 TU), n?=?4, follow-up 12-months. AXO-Lenti-PD was generally well-tolerated with no hypersensitivity, immune response or endotoxicity related adverse events. Two subjects experienced 5 serious adverse events, all unrelated to AXO-Lenti-PD. Subjects continued to show improvements from baseline in UPDRS Part III (Motor) OFF: 14-27 points in low-dose subjects at 24-months and 5-23 points in two UPDRS-evaluable mid-dose subjects at 12-months. Changes from baseline in UPDRS Part II (Activities of Daily Living) OFF of 8-19 points in low-dose subjects at 24-months and 0-8 points in two UPDRS-evaluable mid-dose subjects at 12-months were reported. One low-dose subject completed the Hauser diary at 24-months and had an increase from baseline in good ON time (ON without dyskinesia plus ON with non-troublesome dyskinesia) of 2.0 hours and a mean decrease from baseline in OFF time of 0.5 hours. Mid-dose subjects at 12-months reported a mean increase from baseline in good ON time of 1.8 hours and a mean decrease from baseline in OFF time of 2.1 hours. Further evaluation of AXO-Lenti-PD is planned using a higher dose/volume open label cohort followed by a sham-controlled study.
Phase 1/2 Trial of AXO-AAV-GM1 Gene Therapy for the Treatment of Infantile- and Juvenile-onset GM1 Gangliosidosis
C Tifft12 P D'Souza12 J M Johnston12 M T Acosta12 E R Nicoli12 C Rothermel12 A Thurm13 A Karunakara4 B Thorp4 P Ross4 J Jameson4 M Sheehan4 T Vaughn4 D Valencia4 E De Boever4 G Corcoran4
1: National Institutes of Health 2: National Human Genome Research Institute 3: National Institute of Mental Health 4: Sio Gene Therapies Inc.
Data is presented from an ongoing open-label, single-arm, dose-ranging Phase 1/2 trial (NCT03952637) of an investigational gene therapy AXO-AAV-GM1 (AAV9-GLB1) for treatment of GM1 gangliosidosis which is a rare, fatal, neurodegenerative lysosomal storage disorder. Subjects are administered AXO-AAV-GM1 intravenously following immune modulation with rituximab, sirolimus and glucocorticoids. Seven subjects have been enrolled in 2 cohorts: low-dose (1.5x1013 vg/kg), n?=?4 late-infantile-onset and n?=?1 juvenile-onset, follow-up 12-months; high-dose (4.5x1013 vg/kg), n?=?2 juvenile-onset, follow-up 6-months. AXO-AAV-GM1 was generally safe and well-tolerated. There were two serious adverse events unrelated to AXO-AAV-GM1. Six subjects had adverse events of AST or ALT elevations (≤5X above baseline) that did not require clinical intervention or have associated clinical sequelae and no adverse events of elevations in GGT or bilirubin were reported. At 6-months, CSF GM1 ganglioside was reduced to published normal levels and serum ß-gal enzyme activity increased above the lower limit of normal reference levels in the high-dose subjects. At 12-months, the CSF GM1 ganglioside remained below baseline levels in all low-dose subjects and serum ß-gal activity remained above baseline levels in two of five subjects. Volumetric MRI data in low-dose subjects showed maintenance of brain volume in four of five subjects at 12-months. There was no clinical evidence of disease progression in four of five low-dose subjects at 12-months or in the high-dose cohort at 6-months post-treatment as assessed by Vineland-3, Upright/Floor Mobility Score, Clinical Global Impression, and neurological examination. Further evaluation of these subjects is ongoing.
Bicistronic AAV gene therapy for Tay-Sachs and Sandhoff diseases in a sheep model
T Taghian D Fernau K Mercado L Ellis E Diffie A Gross A Maguire A Batista S Bertrand M Otero R Prestigiacomo R Gately J Gallagher H Lahey A Taylor J Koehler D Martin M Sena-Esteves1 H Gray-Edwards
1: University of Massachusetts Medical School 2: Auburn University 3: Tufts Cummings School of Veterinary Medicine
Tay-Sachs and Sandhoff diseases (TSD, SD) are fatal neurodegenerative disorders, caused by mutations in alpha or beta subunit of enzyme Hexosaminidase (Hex), respectively, and result in GM2 ganglioside storage and neuronal death. Here we describe therapeutic efficacy of a bicistronic AAV9 vector construct in naturally occurring sheep model of TSD. TSD sheep were injected with 1E14 vg total intravenously (IV, n?=?5) or via cerebrospinal fluid (CSF, n?=?9). Sheep treated IV survived to 18?±?5 months and CSF treated sheep are ongoing with the oldest now more than 3 years old. Untreated TSD sheep reach humane endpoint at ~9 months. GM2 levels in CSF of sheep treated by CSF administration were normalized starting at 1 month after treatment and remained in normal range up to 2 years, however, GM2 levels in IV cohort remained above normal. CSF treatment resulted in HexA activity at above normal levels in central nervous system (CNS), however, for IV cohort only lumbar spinal cord reached normal level. HexA expression in peripheral nervous system (PNS) was similar for both cohorts. GM2 levels in CNS and PNS were in line with HexA levels. Vector genome content in CNS was consistent with HexA levels, however, IV treatment except for optic nerve resulted in higher number of virus particles in PNS. Magnetic resonance spectroscopy of treated sheep thalamus showed normalization of neuronal health markers, myelination and metabolism in CSF cohort and slight improvements in IV cohort. Both cohorts exhibited marked attenuation of neurologic disease and normal cognition in neurological examination.
Good luck and GOD bless,
SIOX: Abstracts out. Nice PM volume.
https://www.liebertpub.com/doi/full/10.1089/hum.2021.29180.abstracts
Michael J. Fox on Raising $1 Billion to Help Find Parkinson’s Cure: ‘I Won’t Stop Until It Happens’
https://www.google.com/amp/s/variety.com/2021/scene/news/michael-j-fox-parkinsons-disease-foundation-1235091451/amp/
Gene therapy although not a cure for Parkinson’s disease may seem like one to someone afflicted with Parkinson’s disease.
AXO-Lenti- PD
Parkinson’s Disease: AXO-Lenti-PD
Dopamine DiagramParkinson’s disease is a progressive neurodegenerative disorder that is caused by the loss of dopamine signaling in the brain and results in the continual decline of motor control and quality of life. While there is currently no cure for the disease, through dopaminergic strategies that temporarily increase dopamine levels in the brain, patients see a short-term improvement in symptoms which wanes with disease progression.
AXO-Lenti-PD is the only investigational gene therapy for Parkinson’s disease that delivers the three key genes (TH, CH1, and AADC) required for endogenous dopamine synthesis in a single lentiviral vector. The goal of this one-time infusion is to restore steady, tonic levels of dopamine, potentially reducing the need for daily L-dopa medication while stabilizing the disease to provide long-lasting benefits. Initial clinical data demonstrate that a single dose of AXO-Lenti-PD “turns back the clock” for patients by improving motor function and activities of daily living. AXO-Lenti-PD has been optimized from ProSavin, an earlier gene therapy for the treatment of Parkinson’s disease.
SUNRISE-PD Design
We are currently evaluating AXO-Lenti-PD in a Phase 2 clinical trial (SUNRISE-PD) in patients with moderate to advanced Parkinson’s disease
https://siogtx.com/programs/
Good luck and GOD bless,
SIOX: Nice end of day flurry to close Green.
Expect ABSOLUTELY GREAT NEWS from Sio Gene Therapies this Thursday 21 October 2021.
Good luck and GOD bless,
Penny Stocks To Watch On October 21: Sio Gene Therapies (NASDAQ:SIOX)
Sio Gene’s pipeline focuses on neurodegenerative diseases and includes gene therapies for gangliosidosis and Tay-Sachs/Sandhoff diseases. Its AXO-AAV-GM1 and GM2 are the primary treatment platforms under development. GM1, in particular, has also received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA. Additionally, the company’s AXO-Lenti-PD is in trials for treating Parkinson’s disease.
What To Watch With SIOX Stock This Week
Heading into mid-week, the company presents at the European Society of Gene & Cell Therapy Virtual Congress. This isn’t just a presentation on the broader strokes of the company; Managemen presents new clinical and preclinical data in 2 oral presentations and one poster presentation. These will include an update on the Phase 1/2 trial of AXO-AAV-GM1 in Typ 1 and Type 2 GM1 gangliosidosis. Sio Gene also presents a poster review of data from its Phase 1/2 study of AXO-Lenti-PD.
https://starlocalmedia.com/10-top-penny-stocks-to-watch-this-week-with-potential-biotech-catalysts/article_4a97df85-8444-5e1f-8e03-65c5b10d5634.html
Good luck and GOD bless,
It appears that someone or some tute bought over $1,320,000 worth of SIOX at 11:56 AM on Friday 8 October 2021.
That seems to be a rather big bet BEFORE the coming NEWS next week.
Good luck and GOD bless,
Buy SIOX stock this week BEFORE the NEWS coming next week!!
Good luck and GOD bless,
Sio Gene Therapies Inc. (SIOX) Stock is expected to grow
By
Melanie Gerald
October 9, 2021
Chardan Capital Markets raised the price target for the Sio Gene Therapies Inc. (NASDAQ:SIOX) stock to “a Buy”. The rating was released on July 12, 2021. The research report from H.C. Wainwright has reiterated the stock to Buy, with a price target set at $8. The stock was reiterated by H.C. Wainwright, who disclosed in a research note on April 30, 2021, to Buy and set the price objective to $8. In their research brief published April 30, 2021, H.C. Wainwright analysts initiated the Sio Gene Therapies Inc. stock to Buy with a price target of $8.
Currently, 27.10 percent of Sio Gene Therapies Inc. shares are owned by insiders, and 30.40 percent are held by financial institutions. Cheruvu Pavan, the Chief Executive Officer at Sio Gene Therapies Inc. (SIOX) has bought 100,000 shares of firm on Mar 23 at a price of $2.48 against the total amount of $0.25 million. In another inside trade, Pande Atul, Director of Sio Gene Therapies Inc. (NASDAQ:SIOX) bought 10,000 shares of the firm on Nov 24 for a total worth of $23399.0 at a price of $2.34.
https://bovnews.com/market/sio-gene-therapies-inc-siox-stock-is-expected-to-grow/
Good luck and GOD bless,
SIOX | Sio Gene Therapies
Jun 15
Price target increased to US$8.42
Up from US$7.75, the current price target is an average from 5 analysts.
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-siox/sio-gene-therapies
Good luck and GOD bless,
3 Penny Stocks to Watch in October 2021
Sio Gene Therapies Inc. (NASDAQ: SIOX)
Sio Gene Therapies Inc. is a biotech penny stock that has seen some solid momentum in the past few days. While SIOX stocks performance this year is nothing to write home about, the company does have some interesting prospects. For those unfamiliar with Siox, it is a company that creates gene therapies for those with neurodegenerative diseases. It currently is developing AXO-Lenti-PD which is in Phase 2 clinical trials to treat Parkinson’s disease. The company is also developing AXO-AAV-GM1 which is in Phase 1 / 2 trials to treat GM1 gangliosidosis.
On October 4th, the company released a new update that impacted its stock price. Sio Gene stated that it will present new data at the European Society of Gene and Cell Therapy Virtual Congress 2021. The company will present new clinical and preclinical data via two oral presentations from October 19th to October 22nd. These presentations will include an update on its Phase 1 / 2 trial of AXO-AAV-GM1, for treating GM1 gangliosidosis.
The company will also present a poster review of patient-level data up to 24 months from the Phase 1 / 2 study of AXO-Lenti-PD for Parkinson’s disease. Presentations are always exciting for investors to consider as they allow for new insight into a company’s business. Based on this development, will SIOX make your penny stocks watchlist in October?
https://www.kpvi.com/interests/3-must-watch-penny-stocks-for-your-watchlist-right-now/article_e865820d-dc12-59ca-a4de-f3f3203f3a29.html
Good luck and GOD bless,
The SIOX stock price could reach a new all time high by or before the time next year in 2022.
Good luck and GOD bless,
Just 2 weeks from TODAY, a fortnight.
Oral Presentation Details:
Presentation Title: Phase 1/2 Trial of AXO-AAV-GM1 Gene Therapy for the Treatment of Infantile- and Juvenile-onset GM1 Gangliosidosis
Presentation Number: OR28
Session: Session 4a: CNS & Sensory II
Presenting Author: Erica De Boever, Ph.D., DDS, MPH, Vice President of Clinical Development at Sio Gene Therapies
Presentation Date and Time: Thursday October 21, 2021; 9:00-11:00 AM CEST
Presentation Title: Bicistronic AAV Gene Therapy for Tay-Sachs and Sandhoff Diseases in a Sheep Model
Presentation Number: OR30
Session: Session 4a: CNS & Sensory II
Presenting Author: Toloo Taghian, Ph.D., University of Massachusetts
Presentation Date and Time: Thursday, October 21, 2021; 9:00-11:00 AM CEST
Poster Presentation Details:
Presentation Title: Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease: Efficacy, Safety, and Tolerability Data up to 24 Months
Poster Number: P254
Presenting Author: Gavin Corcoran, MD, Chief R&D Officer of Sio Gene Therapies
Good luck and GOD bless,
AXO-Lenti-PD
AXO-LENTI-PD: POTENTIALLY TURNING BACK THE CLOCK FOR PATIENTS WITH
PARKINSON’S DISEASE
AXO-Lenti-PD achieved up to 10-fold increases in dopamine + L-Dopa production and increased AADC activity compared to ProSavin ® (OXB-101)
Watch the following video of the older ProSavin treatment
TOMORROW TUESDAY 5 October 2021
Presentation
Pavan Cheruvu, MD, Chief Executive Officer
Tuesday, October 5th
9:00 AM ET
Alliance for Regenerative Medicine: Cell & Gene Meeting on the Mesa
https://wsw.com/webcast/chard9/siox/1887025
Good luck and GOD bless,
Followers
|
12
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
255
|
Created
|
03/08/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |